Semax vs Selank: Key Differences for Research

Semax and Selank are both synthetic heptapeptides developed in Russia and studied as research nootropics. The simplest distinction: Semax is most studied in the context of cognition and neuroprotection, while Selank is most studied for anxiolytic (calming) effects.

Research use only. Both compounds are supplied for in-vitro laboratory research. Neither is a medicine, and neither is for human or veterinary consumption, administration, or therapeutic use.

Semax is derived from a fragment of adrenocorticotropic hormone, ACTH(4–10), and in research is associated with brain-derived neurotrophic factor (BDNF) and neurotrophic signalling. Selank is derived from the immunopeptide tuftsin and in research is associated with GABAergic signalling and immune modulation. Different parent molecules, different studied pathways.

In laboratory research, Semax is examined more often in models of attention, memory and neuroprotection; Selank is examined more often in models of anxiety-like behaviour and stress. Researchers studying cognition-focused questions tend to look at Semax, while those studying anxiolytic mechanisms tend to look at Selank — though the two are sometimes investigated together.

Both peptides have Russian clinical history but neither holds a UK marketing authorisation; both are supplied strictly for laboratory research. As with any research peptide, verify identity and purity against a batch-matched Certificate of Analysis (COA). View Semax and Selank product details and COAs.